The writer cites a 52% fall in commercially insured residents using GLP-1s for weight loss after insurers cut coverage, and argues for keeping it for eligible patients.
Recap by typeshit. Full story at The Boston Globe.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Lilly is lowering what it charges for one of its weight loss drugs. The headline doesn't say which drug or by how much.
Access to Ozempic, Wegovy and Mounjaro in Australia often comes down to who can pay, raising the question of public subsidies.
HealthcareAIGuy says the two drugs earned about four times the AI labs' combined revenue, while only around 2% of people with obesity worldwide take them.
In her second month on the drug, she says the scale hasn't moved since stepping up to 5 mg and an itch has spread over her body. She asks others if they've had the same.
Bazaar looks at how the beauty business is reacting to GLP-1 side effects, from 'Ozempic face' to worries about collagen loss and loose skin.
Loading…